AR and neoplasm: Another potential non-kinase target is actually the AR itself (Bisson et al., 2007), which can complicate the interpretation of our experiments, although the fact that mice treated concomitantly with J54 and BIC (which is a much more powerful anti-androgen) show strong tumor regression argues against the idea that the two drugs act on the same pathway.